Bravecto 150 mg/ml Powder and Solvent for Suspension for Injection for Dogs

Parasites need to start feeding on the host to become exposed to fluralaner;
therefore, the risk of the transmission of parasite borne diseases (including Babesia
canis canis and D. caninum) cannot be completely excluded.
Unnecessary use of antiparasitics, or use deviating from the instructions given, may
increase the resistance selection pressure and lead to reduced efficacy. The decision
to use the veterinary medicinal product should be based on confirmation of the
parasitic species and burden, or of the risk of infestation based on its epidemiological
features, for each individual animal.
The possibility that other animals in the same household can be a source of re-
infection with parasites should be considered, and these should be treated as
necessary with an appropriate veterinary medicinal product.

Special precautions for use in animals
Safety of the product has not been assessed in dogs with pre-existing epilepsy.
Therefore, use with caution in such dogs based on a benefit/risk assessment by the
responsible veterinarian.

Issued: June 2024
AN: 00132/2023
In the absence of available data, the veterinary medicinal product should not be used
on dogs less than 6 months old.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Care should be taken to avoid accidental self-injection and dermal exposure when
administering this veterinary medicinal product.
In case of accidental self-injection, contact a physician and show the label or
package leaflet. Wash hands after use.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.